biotech / news / / The Manila Times
Ohtuvayre® (ensifentrine) helped improve lung function in Chinese adult patients in in data published in peer reviewed journal.
Phase 3 ENHANCE-CHINA trial showed Ohtuvayre significantly improved lung function in Chinese COPD patients.
KEY POINTS
- Ohtuvayre is the first COPD therapy in China with a novel mechanism of action in over 10 years.
- Nuance Pharma's New Drug Application for Ohtuvayre was accepted for review by China's NMPA in January 2026.
- Merck/MSD now holds exclusive Ohtuvayre rights outside of Greater China after acquiring Verona Pharma.
COMPANIES
Summarized by Newsio from The Manila Times. How we summarize →